skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Cancer risks and neutron RBE's from Hiroshima and Nagasaki

Conference ·
OSTI ID:5238862

The new radiation dose estimates for Hiroshima and Nagasaki are here combined with epidemiologic data from the A-bomb survivors and examined radiobiologically for compatability with other human and experimental data. The new doses show certain improvements over the original T65 doses. However, they suggest for chronic granulocytic leukemia, total malignancies, and chromosome aberrations, at neutron doses of 1 rad, RBEs in excess of 100, higher than expected from other findings. This and other indications suggest that either there are unrecognized systematic problems with the various radiobiological data, or the new doses are deficient in neutrons for Hiroshima, by a factor of about five. If in fact there were actually some 5-fold more dose from neutrons at Hiroshima than estimated by the new calculations, the RBEs would agree well with laboratory results, and other inconsistencies would largely disappear. Cancer risks are estimated for neutrons from the new doses and are compared with those estimated from radiobiologically reconciled doses (the new doses adjusted by adding approximately 5-fold more neutrons). The latter estimates appear more reasonable. For low-LET radiation, cancer risk estimates are altered very little by the new dose estimates for Nagasaki.

Research Organization:
Lawrence Livermore National Lab., CA (USA)
DOE Contract Number:
W-7405-ENG-48
OSTI ID:
5238862
Report Number(s):
UCRL-87477-Rev.1; CONF-820344-2-Rev.1; ON: DE82016012; TRN: 82-014147
Resource Relation:
Conference: Symposium on neutron carcinogenesis, Rijswijk, Netherlands, 28 Mar 1982
Country of Publication:
United States
Language:
English